Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives

SIMPLE SUMMARY: Five years of therapy remains the standard for adjuvant endocrine therapy in early breast cancer. However, the recurrence risk remains elevated beyond this time period. Estimating the risk of recurrence as well as the efficacy of therapy is important in the selection of patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekes, Inga, Huober, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453164/
https://www.ncbi.nlm.nih.gov/pubmed/37627218
http://dx.doi.org/10.3390/cancers15164190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453164/
https://www.ncbi.nlm.nih.gov/pubmed/37627218
http://dx.doi.org/10.3390/cancers15164190

Ejemplares similares